Heart failure & cardiomyopathies
Effect of mavacamten and disopyramide on left ventricular mechanical dispersion and life-threatening arrhythmia in obstructive hypertrophic cardiomyopathy
Authors' conclusion
Mavacamten, but not disopyramide, decreased LVMD, GWW, and increased GWE in obstructive HCM. LVMD <72 ms at follow-up is promising for assessing the risk for life-threatening ventricular arrhythmias.
Study context
- Population
- Subjects with obstructive HCM treated with either Mavacamten or disopyramide from 2018 to 2024
- Participants
- 120 consecutive subjects
- Comparison
- Effects of mavacamten and disopyramide on left ventricular mechanical dispersion (LVMD) and its association with life-threatening ventricular arrhythmias
- Outcome
- LVMD with Mavacamten (baseline vs. follow-up)
Methodological detailsPropensity matching was performed for age and sex
- Propensity matching was performed for age and sex
Main finding
As reported in the abstract
LVMD baseline vs. follow-up
85.1 ± 26.4 ms vs. 64.3 ± 16.7 ms
P = 0.013
Further findings
Global wasted work (GWW) with Mavacamten
- GWW baseline vs. follow-up
- 268 mmHg% (185-378) vs. 150 mmHg% (124-262), P = 0.006
Global work efficiency (GWE) with Mavacamten
- GWE baseline vs. follow-up
- 87% (82-92) vs. 90% (86-94), P = 0.038
- Increased
Effects with disopyramide
- None of the favourable effects were observed with disopyramide
LVMD at follow-up and outcome events (sustained ventricular tachycardia (VT) or sudden cardiac arrest (SCA))
- Area under curve
- 0.784, 95% CI (0.622-0.945), P < 0.001
Event-free survival by LVMD <72 ms at follow-up
- LVMD <72 ms associated with improved event-free survival
- X6.4, log-rank P = 0.011
Determinants of LVMD at follow-up
- Mavacamten and global work indices were independent determinants of LVMD at follow-up
Follow-up duration
- Median follow-up duration
- 12 (range 6-24) months
Original publication
Effect of mavacamten and disopyramide on left ventricular mechanical dispersion and life-threatening arrhythmia in obstructive hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. Published 15 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →